Final countdown: How to transition your trials under EU-CTR
Parexel's regulatory experts shared their insight how to transition trials under EU-CTR in a live webinar on April 30. Watch on-demand to find out more about:
- The processes and timescales required to meet the EU-CTR trial transition deadline of 31 January 2025
- Actions that sponsors should take for a smooth transition process and to mitigate the risk of non-compliance as a result of missing the deadline
- Key learnings, insights and tips from regulatory experts with practical experience in how to approach the transition process
- Answers to the queries raised by our audience during the Q&A session
With the deadline for transition approaching fast, we're urging sponsors to begin the transition process for their their trials now to mitigate potential delays and the risk of trials ceasing through non-compliance with EU-CTR.
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Playbook
Are you using real-world evidence?
Feb 1, 2023
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Preparing for the New Era of Hybrid Regulatory Inspections
Jul 11, 2022
Article
EU Orphan Drug Designation – overcoming regulatory challenges
Jul 20, 2022
Video
Cell & Gene Therapies: A Regulatory Update
Jul 22, 2022
Blog
U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?
Aug 17, 2022
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022